As the biotechnology industry matures, the drivers of valuation are evolving: the premium on quality science is rising ever higher while expectations for excellence in commercial execution are sky high.

Torreya’s biotechnology practice has mirrored the evolution of the sector. Much of our work involves fundraising and licensing for early-stage science companies. We have not shied away from assisting companies with high-quality preclinical assets or Phase 1 assets, and we are proud of our track record of closing successful transactions for such companies. At the same time, we provide strategic and financing advice to later-stage companies that face both sophisticated strategic counterparties and increasingly discerning capital markets. We also have been heavily involved in acquisition work for larger biotechnology companies.

Torreya works on all therapeutic areas, and we have substantial expertise in cardiology, gastroenterology, inflammation, oncology, psychology, and vaccines. Our strength is our knowledge of science, the currency, and level of our knowledge of strategic counterparties, and the discipline of our transaction processes.

We bring a scientifically committed team that has been involved in the biotechnology industry since the early days. Our biotechnology advisory team is supported by a strong team of advisors in North America, Europe, and India.


Tim Opler  |  New York  |
Kylor Hua  |  New York  |
Stephanie Léouzon  |  London  |
Kelly Curtin  |  London  |